2. Search Result
Search Result
Results for "

Antileukemia

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111380
    EHT 1610
    1 Publications Verification

    		 DYRK Neurological Disease
    EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis - .
    EHT 1610
  • HY-163677
    ARM165

    		PROTACs PI3K Akt Cancer
    ARM165 is a heterobifunctional molecule. ARM165 degrades the PIK3CG proteins, inhibits PI3Kγ-Akt signaling pathway, and thus exhibits antileukemia efficacy. ARM165 inhibits proliferations of AML cells, with IC50 <1 μM. (Pink: ligand for target protein PI3Kγ inhibitor AZ2 (HY-111570); Black: linker; Blue: ligand for E3 ligase Pomalidomide (HY-10984))
    ARM165
  • HY-18714
    BRD7116

    		Bacterial Others
    BRD7116 competitively binds to bacterial DNA gyrase, exhibits an EC50 of 200 nM for LSCe cells, with cell-non-autonomous anti-leukemia activity.
    BRD7116
  • HY-W011156
    Mpa(Trt)

    		Amino Acid Derivatives Others
    Mpa(Trt) is a 3-mercaptopropionic acid derivative containing a trityl protecting group (Trt) and can be used to synthesize compounds with anti-leukemia activity .
    Mpa(Trt)
  • HY-114162A
    VTP50469 fumarate
    5+ Cited Publications

    		 Epigenetic Reader Domain Apoptosis Cancer
    VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .
    VTP50469 fumarate
  • HY-114162
    VTP50469
    5+ Cited Publications

    		 Epigenetic Reader Domain Apoptosis Cancer
    VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
    VTP50469
  • HY-N14586
    Roridin J

    		Others Cancer
    Roridin J is a macrocyclic trichothecene and has anti-leukemia effect in mice .
    Roridin J
  • HY-163725
    DHFR-IN-18

    		Dihydrofolate reductase (DHFR) Cancer
    DHFR-IN-18 (compound 19D) is a DHFR inhibitor. DHFR-IN-18 can be used in anti-leukemia research .
    DHFR-IN-18
  • HY-N1112
    Uncargenin C

    		Others Cancer
    Uncargenin C is a triterpenoid, which can be isolated from Uncaria rhychophyllo Miq. Jacks. The intermediate of Uncargenin C has anti-leukemia activity, but not itself .
    Uncargenin C
  • HY-161798
    Orpinolide

    		Others Cancer
    Orpinolide is a withanolide analog that has anti-leukemia properties. It disrupts the internal balance of the Golgi apparatus, which is related to signaling through inositol 4-phosphate at the interface of the endoplasmic reticulum and Golgi membrane .
    Orpinolide
  • HY-141844
    HDAC/BET-IN-1

    		HDAC Cancer
    HDAC/BET-IN-1 displays submicromolar inhibitory activity against HDAC1 and 6 (IC50 = 0.163 μM and 0.067 μM), and BRD4 (Ki = 0.076 μM), and possess potent antileukemia activity.
    HDAC/BET-IN-1
  • HY-112475
    Flt-3 Inhibitor III

    		Tie FLT3 Cancer
    Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an 50 of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .
    Flt-3 Inhibitor III
  • HY-14942A
    Berubicin hydrochloride

    RTA 744; WP 744; WP 769 hydrochloride

    		 Apoptosis Cancer
    Berubicin hydrochloride (RTA 744) is a Doxorubicin (HY-15142A) analogue. Berubicin hydrochloride triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. Berubicin hydrochloride has proapoptotic and anti-leukemia activities. Berubicin hydrochloride can be used for cancer research .
    Berubicin hydrochloride
  • HY-N0840
    Bruceantin
    1 Publications Verification

    (-)-Bruceantin; NCI165563; NSC165563

    		 c-Myc Caspase Mitochondrial Metabolism Apoptosis Parasite Infection Cancer
    Bruceantin (NSC165563) can be extracted from B. javanica. Bruceantin activates caspase signaling pathway, causes the mitochondrial dysfunction, inhibits cell proliferation, induces cell differentiation and apoptosis. Bruceantin exhibits anti-leukemia and antiprotozoal activities .
    Bruceantin
  • HY-154971
    Ara-SH

    		Apoptosis Cancer
    Ara-SH is a Cytarabine mercaptopropionic acid-substituted derivative. Ara-SH is used as the trigger to fabricate a smart Cytarabine and Venetoclax-coloaded nanoparticle (AV-NP) through self-assembly. Ara-SH exhibits remarkable synergistic antileukemia effects in vitro and in vivo .
    Ara-SH
  • HY-124007
    4-Iodo-SAHA

    ISAHA

    		 HDAC Cancer
    4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer .
    4-Iodo-SAHA
  • HY-W077242
    1,4-Anthraquinone

    		DNA/RNA Synthesis Cancer
    1,4-Anthraquinone is a potent anticancer agent. 1,4-Anthraquinone blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of cancer cells. 1,4-Anthraquinone can be used to research anti-leukemia .
    1,4-Anthraquinone
  • HY-168860
    Antituberculosis agent-13

    		Bacterial Infection Cancer
    Antituberculosis agent-13 (Compound 11) inhibits Mycobacterium tuberculosis, that inhibits Mtb wildtype and mutated strains with IC50 of 4-62.5 nM. Antituberculosis agent-13 exhibits anti-leukemia activity that inhibits MOLM-13 with IC50 of 3.8 μM .
    Antituberculosis agent-13
  • HY-149805
    Anticancer agent 110

    		Apoptosis Cancer
    Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .
    Anticancer agent 110
  • HY-139193
    TH1760

    		DNA/RNA Synthesis Cancer
    TH1760 is an inhibitor of NUDIX-type 15 (NUDT15) with an IC50 value of 25 nM. TH1760 sensitizes cells to 6-thioguanine by enhancing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 enhances the anti-leukemia effect of thiopurine .
    TH1760
  • HY-168083
    Dot1L-IN-9

    		Histone Methyltransferase Cancer
    Dot1L-IN-9 (Compound 12) is a DOT1L inhibitor (IC50: 125 nM). Dot1L-IN-9 reduces H3K79 dimethylation. Dot1L-IN-9 can be used for anti-leukemia research .
    Dot1L-IN-9
  • HY-158341
    IOX5

    		HIF/HIF Prolyl-Hydroxylase Apoptosis Cancer
    IOX5 is a selective prolyl hydroxylase (PHD) inhibitor with an IC50 of 0.19 μM for PHD2. IOX5 stabilizes HIF-1α in acute myeloid leukemia (AML) cells, inhibits cell proliferation and induces apoptosis. IOX5 has anti-leukemia activity .
    IOX5
  • HY-124069
    M-525

    		Epigenetic Reader Domain Cancer
    M-525 is a first-in-class, highly potent, irreversible and covalent menin-MLL protein-protein interaction inhibitor. M-525 binds to menin with an IC50 of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .
    M-525
  • HY-139147
    iHCK-37

    ASN05260065

    		 Src Infection Cancer
    iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a Ki value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC50 value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research .
    iHCK-37
  • HY-170380
    XY221

    		Epigenetic Reader Domain Apoptosis AMPK c-Myc PAK Bcl-2 Family Cancer
    XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC50 of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity .
    XY221
  • HY-172158
    ALKBH5-IN-5

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALKBH5-IN-5 (compound 18l) is an ALKBH5 inhibitor, exhibiting highly selective inhibitory effect on ALKBH5 with an IC50 of 0.62 μM. ALKBH5-IN-5 exerts a strong antiproliferative effect on NB4 cells with an IC50 of 0.63 μM. ALKBH5-IN-5 binds with ALKBH5 with a Kd of 804 nM. ALKBH5-IN-5 directly targets ALKBH5 in cells and alters m 6A levels on mRNA, blocks the related downstream signal pathways, promotes differentiation, and induces Apoptosis. ALKBH5-IN-5 exerts excellent in vivo antitumor activity with TGITV values of 66.3% .
    ALKBH5-IN-5
  • HY-120997
    E6 Berbamine

    Berbamine p-nitrobenzoate

    		 Calmodulin Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activity of calmodulin (CaM)-dependent myosin light chain kinase (MLCK), with a Ki of 0.95 μM . E6 Berbamine also shows anti-leukemia activities, with an IC50 of 2.13 μM in K562 cells .
    E6 Berbamine
  • HY-170323
    4-TM.P

    		Apoptosis Cancer
    4-TM.P binds to the minor groove of DNA, inhibits proliferation of cancer cell K562 with an IC50 of 25 µM, arrests the cell cycle at G0/G1 phase, and induces apoptosis in cell K562. 4-TM.P can be used in anti-leukemia research .
    4-TM.P
  • HY-13765
    6-Thioguanine
    Maximum Cited Publications
    10 Publications Verification

    Thioguanine; 2-Amino-6-purinethiol

    		 SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite Infection Inflammation/Immunology Cancer
    6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
    6-Thioguanine
  • HY-162462
    Antitumor agent-151

    		Apoptosis Cancer
    Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .
    Antitumor agent-151
  • HY-150109
    Purinostat mesylate

    		HDAC Apoptosis Cancer
    Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia .
    Purinostat mesylate
  • HY-161516
    HDAC6-IN-42

    		HDAC Cancer
    HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC50=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research .
    HDAC6-IN-42
  • HY-168073
    EGFR/VEGFR2-IN-1

    		EGFR VEGFR Apoptosis Microtubule/Tubulin Cancer
    EGFR/VEGFR2-IN-1 (Compound 10e) is a VEGFR-2 and EGFR inhibitor (IC50: 0.26 and 0.14 μM respectively). EGFR/VEGFR2-IN-1 inhibits tubulin polymerization with an IC50 of 40.9 μM. EGFR/VEGFR2-IN-1 induces apoptosis. EGFR/VEGFR2-IN-1 can be used for research of antileukemia and antilymphoma .
    EGFR/VEGFR2-IN-1
  • HY-30272
    Monobenzone
    1 Publications Verification

    		 Biochemical Assay Reagents Apoptosis DNA/RNA Synthesis Cancer
    Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .
    Monobenzone
  • HY-172364
    PLK1-IN-12

    		Polo-like Kinase (PLK) Cancer
    PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .
    PLK1-IN-12
  • HY-13765R
    6-Thioguanine (Standard)

    		SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite Infection Inflammation/Immunology Cancer
    6-Thioguanine (Standard) is the analytical standard of 6-Thioguanine. This product is intended for research and analytical applications. 6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
    6-Thioguanine (Standard)
  • HY-149539
    PLM-101

    		FLT3 RET Cancer
    PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .
    PLM-101
  • HY-168936
    DP-15

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    DP-15 is the degrader for GSPT1 and BRD4 with DC50s of 5.25 nM and 0.48 nM. DP-15 exhibits anti-proliferative activity of AML cells and NHL cells with an IC50 of nanomolar levels, arrests the cell cycle at G1 phase, and induces apoptosis in MOLM13. DP-15 exhibits anti-leukemia activity in MOLM-13 xenograft mouse models . (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W262798); Blue: ligand for E3 ligase Cereblon Thalidomide-5-OH (HY-23095))
    DP-15
  • HY-163678
    Pomalidomide-CO-C7-NH-CO-C3-COOH

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide-CO-C7-NH-CO-C3-COOH is a conjugate of a ligand for E3 ligase and a linker. Pomalidomide-CO-C7-NH-CO-C3-COOH can be used for synthesis of PROTAC degrader ARM165 (HY-163677) .
    Pomalidomide-CO-C7-NH-CO-C3-COOH